DNLI News and Press, Denali Therapeutics Inc.

2026-03-06 15:55:57 ET Denali Therapeutics Inc. (DNLI) TD Cowen 46th Annual Health Care Conference March 4, 2026 9:50 AM EST... Read the full article on Seeking Alpha For further details see: Denali Therapeutics Inc. (DNLI) Presents at TD Cowen 46th Annual Health Care Confer...

2026-03-02 20:03:59 ET Andrew Tsai from Jefferies issued a price target of $40.00 for DNLI on 2026-03-02 22:08:00. The adjusted price target was set to $40.00. At the time of the announcement, DNLI was trading at $21. The overall price target consensus is at $33.00 with ...

2026-02-26 17:06:24 ET More on Denali Therapeutics Denali Therapeutics Inc. (DNLI) Presents at 22nd Annual WORLDSymposium - Slideshow Denali Therapeutics Inc. (DNLI) Shareholder/Analyst Call Transcript Denali Therapeutics Inc. (DNLI) Shareholder/Analyst Call - Slides...

Tividenofusp alfa (DNL310; ETV:IDS) launch readiness established ahead of April 5, 2026 Prescription Drug User Fee Act (PDUFA) target action date for Hunter syndrome DNL126 (ETV:SGSH) Phase 1/2 preliminary data presented at 2026 WORLD Symposium™ , supporting plans to pursue an accele...

Evertec Inc. (EVTC) is expected to report $0.81 for Q4 2025 BioCryst Pharmaceuticals Inc. (BCRX) is expected to report $0.06 for Q4 2025 FTI Consulting Inc. (FCN) is expected to report $1.38 for Q4 2025 Arbe Robotics Ltd. (ARBE) is expected to report $-0.1 for Q4 2025 Aclaris Ther...

AUSTIN, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage : Biotechnology mergers and acquisitions (M&As) are increasingly shaped by a clear strategic evolution. Pharmaceutical companies are prioritizing clinical-stage and late-stage programs supported by human data...

2026-02-06 16:14:36 ET Denali Therapeutics Inc. (DNLI) Shareholder/Analyst Call February 5, 2026 3:30 PM EST... Read the full article on Seeking Alpha For further details see: Denali Therapeutics Inc. (DNLI) Shareholder/Analyst Call Transcript

Analysis from continued follow-up of Phase 1/2 clinical trial data in Hunter syndrome (MPS II) reinforces potential for tividenofusp alfa (DNL310) to address full disease spectrum Launch readiness established in anticipation of April 5, 2026, Prescription Drug User Fee Act (PDUFA) date for tivid...

SOUTH SAN FRANCISCO, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that management will host a live webcast to review presentations on its Enzyme TransportVehicle™ (ETV) programs at the upcoming 22nd Annual WORLD Symposium ™ being ...

Hunter syndrome (MPS II) presentations will include analysis from continued follow-up of Phase 1/2 data for tividenofusp alfa (DNL310), currently under FDA Priority Review Preliminary data from Phase 1/2 study of DNL126 (ETV:SGSH) for Sanfilippo syndrome type A (MPS IIIA) to be featured in oral ...